| 83 |
Laboratory Research
|
Antimicrobial advanced wound care dressing G. Schultz, B. Liesenfeld, C. Batich, R. Carr, G. Olderman, Quick-Med Technologies, Gainesville, FL.. Quick-Med Technologies (QMT) has developed a patented process (NIMBUSä) that permanently attaches a quaternary ammonium-based polymeric microbicidal agent onto a range of physical substrates. The process has been shown to provide effective protection against pathogenic bacteria (including Staphylococcus aureus, Escherica Coli , Pseudomonas aeruginosa, MRSA, VRE ), viruses and fungi. Extraction testing and zone of inhibition testing show no leaching of the microbicidal agent from the substrate. Standard toxicological testing demonstrates that the agents utilized are harmless to normal cells. NIMBUS dressings have been prepared successfully on a range of substrates that include cellulosics (cotton, rayon) as well as more advanced wound dressing substrates such as polyurethane foams and CMC fibers. .Current commercially available antimicrobial dressings have clearly demonstrated to improve healing on chronic wounds, and improve patient outcomes, but are generally based on leaching microbicides. High cost, and the possibility of patients developing resistance to leached agents such as silver or antibiotics, has made prophylactic use of these materials potentially problematic. .NIMBUSä dressings represent a novel category of materials that can be economically and safely applied as prophylactics to prevent the progression of low-level colonized wounds to infected wounds. The manner of bacterial control is non-leaching and based on cell-wall disruption Ñ both of these traits minimize the possibility of pathogens generating resistance. The treatment adds comparatively small incremental costs to the production of a normal untreated dressing and is easily incorporated into current manufacturing systems. Overall savings are achieved while improving patient outcomes. . Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Rep Regen. 2003;11 suppl 1:S1ÐS28 Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Regen. 1999;7(5):335Ð346 Robson MC. The role of growth factors in the healing of chronic wounds. Wound Rep Regen. 1997;5:12Ð17 Falanga V. Apligraf treatment of venous ulcers and other chronic wounds. J Dermatol. 1998;25(12):812Ð817 Trengove NJ, Stacey MC, Macauley S, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Regen. 1999;7(6):442Ð452 Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Rep Reg. 1996;4:411Ð420 Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Rep Regen. 2002;10(1):26Ð37 Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev. 2003;27:341Ð353.. |
|